Event Agenda Includes a Press Conference on Capitol Hill, Medical Marijuana Briefing With Hill Staff, Lobbying, Panel Discussions Including Cannabidiol (CBD), and Excellence Awards
SAN DIEGO, April 3, 2014 (GLOBE NEWSWIRE) — Medical Marijuana Inc. (OTC Pink:MJNA) is pleased to announce that its subsidiary company, HempMedsPX™, will participate in the Americans for Safe Access (ASA) 2nd Annual National Medical Cannabis Unity Conference, Navigating Medical Cannabis in the Mainstream, in Washington D.C. The conference takes place at the Mayflower Renaissance Hotel April 5 – 7, 2014. ASA‘s goal is to express “strength in unity” to the current administration with regard to changing policies that prevent safe access to cannabis. Cannabidiol (CBD) is a hot topic that HempMedsPX™ will discuss with medical doctors, legal experts, and policymakers during ASA‘s Unity Conference.
“We appreciate all that ASA is doing to educate the public about safe access to medical cannabis,” states Charles Vest, VP of Communications for HempMedsPX™. “We are participating in ASA‘s Unity Conference to convey our belief that there needs to be ‘access for all.'”
In 2013, ASA donors sponsored 125 patients from thirty-four states to attend the national conference. These patients participated in the largest medical cannabis lobby day in US history visiting more than 300 Congressional offices that day.
“We are so fortunate to have HempMeds joining us as Partnering Sponsor at this year’s Unity Conference,” states Steph Sherer, Executive Director of Americans for Safe Access. “Their generous contribution helped ASA grant scholarships to 152 advocates from 37 states who will be bringing their messages to the halls of Congress.”
ASA‘s Unity Conference agenda includes presentations on the history of botanical medicines in the US, the future of regulation and product safety, and a panel discussion: “CBD the Myths and the Facts.” The conference includes a trip to Capitol Hill. There, ASA will host a press conference, brief Hill staff on medical marijuana, and lobby Capitol Hill with hundreds of patient advocates.
One of Medical Marijuana, Inc.‘s investment holdings is KannaLife Sciences, Inc., a socially responsible, bio-pharmaceutical and phyto-medical company specializing in the research and development of pharmacological products derived from plants. Current target drug candidates are to treat Hepatic Encephalopathy (HE) and Chronic Traumatic Encephalopathy (CTE). KannaLife Sciences, Inc. is involved in the research and development of novel therapeutic agents designed to reduce oxidative stress and act as immuno-modulators and neuroprotectants and currently holds an exclusive license agreement with the National Institutes of Health – Office of Technology Transfer (NIH-OTT) for the commercialization of U.S. Patent #6,630,507, “Cannabinoids as Antioxidants and Neuroprotectants” (the “‘507 Patent”). The Company’s Chairman and Chief Executive Officer will take part in ASA‘s panel discussion: “CBD the Myths and the Facts.”
“Acceptance of cannabis as a natural product is spreading nationwide. Until nationwide cannabis legalization is achieved, we simply want to give people without access another choice with our CBD-rich hemp oil products. Between more and more states legalizing medical marijuana, and the reintroduction of hemp agriculture thanks to the 2014 Farm Bill, this is an exciting time to be part of the effort to legalize cannabis for all,” Vest concludes.
For more information on CBD-rich hemp oil products, please visit:
HempMedsPX offers mainstream marketing, sales, customer service, and logistics for the cannabis industry. HempMedsPX is a corporate portfolio company of Medical Marijuana, Inc. (OTC Pink:MJNA) and the Company’s exclusive master distributor and contracted marketing company. In addition to handling sales and distribution, HempMedsPX is the communication hub for the Medical Marijuana Inc. portfolio of companies.
About Medical Marijuana Inc.
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For more information, please visit the company’s website at: www.MedicalMarijuanaInc.com
About KannaLife Sciences
KannaLife Sciences, Inc. (“KannaLife”) is a late-stage biopharmaceutical and phyto-medical technology company. KannaLife was created to develop natural, phyto-medical products to be used in health and wellness regimens. KannaLife is currently conducting research and development of novel new therapeutic agents to be used as transport carriers for other compounds seeking to break the blood/brain barrier. KannaLife is also developing their own compounds to be used for the treatment and prevention of oxidative and neurotoxic stresses borne from a variety of ailments and illnesses. For more information, visit KannaLife.com.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana Inc. to be materially different from the statements made herein.
Medical Marijuana Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). The company does grow, sell and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.
For further information, please contact:
Investor relations contact:
Medical Marijuana, Inc.